Bioniz Therapeutics announces positive data from BNZ-1 phase 1/2 trial in rCTCL

TAGS

Bioniz Therapeutics has announced positive data from a phase 1/2 clinical trial of BNZ-1 for the treatment of relapsed or refractory cutaneous T-cell lymphoma (rCTCL).

BNZ-1 is an immuno-modulator drug candidate. It is a multi-cytokine inhibitor of three interleukins, that includes IL-2, IL-9, and IL-15.

It is the lead asset from Bioniz Therapeutics’ platform of first-in-class peptide therapeutics that inhibit selectively and simultaneously multiple cytokines for treating cancer and autoimmune diseases.

See also  Monarch Tractor raises $20m for manufacturing smart tractors

Dr. Nazli Azimi – Founder, President, and CEO of Bioniz Therapeutics and co-inventor of BNZ-1, said: “These data validate our platform technology with the first efficacy demonstration of BNZ-1, a novel multi-cytokine inhibitor, and assisted us in the design of a pivotal clinical trial for CTCL, which the company expects to begin in 2021.

“We believe the efficacy of BNZ-1 in rCTCL, a challenging and progressive disease, is due to the drug’s multi-modal mechanism of action. BNZ-1 was specifically designed as a multi-cytokine inhibitor to integrate inhibition of malignant cells, activation of tumor immunity, and suppression of inflammation.

See also  Mindtree to drive digital transformation for Western Asset Management

“In addition to the positive efficacy data, we are extremely encouraged that the BNZ-1 treatment was well tolerated, which could support long-term treatment for these patients.”

The phase 1/2 clinical trial was designed as a multi-center, open-label, dose-escalation study of BNZ-1 to evaluate its safety and activity as a single systemic agent in rCTCL patients who failed the standard of care and other available treatment options, which include up to seven prior skin-directed and systemic therapies.

See also  World Insurance Associates acquires New Jersey-based Szerlip & Co.

The primary endpoint of the early-stage trial was overall safety following four weeks of treatment. There was a three-month treatment extension to assess the safety and clinical response further at week 17.

CATEGORIES
TAGS
Share This